CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 44 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Placebo 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02475564
NCT02475564Phase 4Completed
CompareCT.gov

The Use of Resveratrol for Pain in Endometriosis - A Clinical Trial

Hospital de Clinicas de Porto Alegre·interventional·Posted Jun 18, 2015·Updated Oct 14, 2016

In Brief

A Phase 4 clinical trial evaluating Placebo and Resveratrol for Endometriosis. Completed, enrolled 44 participants across 1 site.

Detailed Summary

This study aims to verify whether the use of 40 mg of resveratrol per day associated with monophasic contraceptive pill (levonorgestrel 0.15mg/ethinyl estradiol 0.03mg) reduces pelvic pain at the end of 2 months of treatment, compared to the use of the pill with placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometriosis
CountriesBrazil
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 18, 2015
Enrollment StartJun 1, 2015
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11.0 years ago

Interventions

Placebodrug

40mg of starch

Resveratroldrug

40mg of resveratrol (powder)